Not Yet RecruitingNot Applicable

RANDOMIZED CONTROLLED TRIAL OF TEXT MESSAGE TO INCREASE PNEUMOCOCCAL VACCINATION IN ADULTS IN CHILE.

Chile43,000 participantsStarted 2026-07-15

Plain-language summary

The goal of this randomized controlled trial is to learn if text message reminders sent through WhatsApp increase pneumococcal vaccination coverage in adults turning 65 years old in Chile. The main questions it aims to answer are: Do text message reminders increase the proportion of adults aged 65 years who receive the pneumococcal vaccine compared to usual care? Do text message reminders increase pneumococcal vaccination coverage within the first 7 days after the message is sent? Is there an association between socioeconomic factors and pneumococcal vaccination coverage in adults aged 65 years in Chile? Researchers will compare adults who receive a text message reminder to adults who receive no reminder (usual care) to see if the reminders increase vaccination uptake. Participants will: Be randomly assigned to receive a WhatsApp text message reminder about the pneumococcal vaccine or to receive no reminder Receive a second reminder on day 14 if they have not yet been vaccinated (intervention group only) Be followed for 6 weeks, with vaccination status checked at days 7, 21, and 42 from the start of the intervention

Who can participate

Age range

64 Years – 65 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults born during the year 1961, turning 65 years of age in 2026 * Resident in Chile at the time of the study * Valid mobile phone number registered in the National Immunization Registry (RNI) Exclusion Criteria: * Record of pneumococcal vaccination in the National Immunization Registry (RNI). * Identified as deceased in the Chilean Civil Registry and Identification Service.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Pneumococcal vaccination coverage at day 42

Timeframe: 42 days from the start of the intervention

Trial details

NCT IDNCT07659470

SponsorPablo Tomás Valenzuela García

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-09-01

Contact for this trial

Pablo Valenzuela García, MD, MSc

56 223543508 povalenzuela@uc.cl

View on ClinicalTrials.gov More Pneumococcal Infections trials